NEWS

• Suvoda Announces Agentic RTSM, Enabling The Reduction Of Clinical Trial Startup Timelines By Up To 80%

  The next evolution of Suvoda IRT is designed to accelerate study builds and change orders, elevate user experience, and deliver intelligent insights

• Signant Health Enters Definitive Agreement To Acquire Ametris

  Signant Health, the evidence generation company, today announced that it has entered into a definitive agreement to acquire Ametris (formerly ActiGraph), a global digital health solutions provider, subject to customary regulatory processes and approvals and closing conditions.

• Crucial Data Solutions Expands TrialKit AI With Study Simulation And Validation Capabilities
• AI HealthTech Pioneer Biorce Opens U.S. Offices In Austin To Accelerate Global Expansion

  Biorce expands its U.S. footprint and AI R&D operations by opening a new office in Austin, Texas this week. In Europe, Biorce is already rapidly transforming how Phase I–III clinical trials—up to market approval—are developed.

• Signant Health Appoints Specialist Physician And Clinical Research Expert Dr. Graham C. Ellis As Clinical Vice President To Strengthen Metabolic Disease And Diabetes Trial Capabilities

  Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Dr. Graham C. Ellis as Clinical Vice President. With more than 25 years of experience as a specialist physician and clinical researcher in diabetes, endocrinology, and metabolic disease, Dr. Ellis brings extensive scientific depth and a distinguished track record as a Principal Investigator across more than 150 international Phase 2–4 clinical trials. His appointment strengthens Signant’s capabilities in supporting sponsors developing treatments in metabolic disease, obesity, and related therapeutic areas.

• Suvoda Advances Clinical Trial Financial Planning With Support For Complex Multi-Payee Budgets

  Suvoda, a clinical trial technology company, today announced new split budget functionality within its Budgeting & Benchmarking solution, expanding how sponsors and CROs can manage complex site budget development across global studies and helping to accelerate the up-front work of clinical trials.

• Suvoda Named "Most Innovative Clinical Trial Technology Firm Of 2026"

  Suvoda, a global leader in clinical trial technology, has been recognized as the Most Innovative Clinical Trial Technology Firm of 2026 in the Global Excellence Awards presented by Global Health & Pharma magazine. This accolade recognizes Suvoda’s leadership in advancing clinical trial software solutions that empower sponsors, CROs, patients, and study sites with streamlined operations and real-time insights.

• Avance Clinical Appoints Liahna Toy To Lead Global Early Phase Center Of Excellence

  Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing biotech, announces the appointment of Liahna Toy as Senior Vice President & Head of Early Phase Center of Excellence, reinforcing the company’s strategic focus on accelerating high-quality early-phase trials for emerging biotech sponsors.

• Avance Clinical Strengthens Global Oncology Offering With Acquisition Of U.S-Based LumaBridge

  Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, today announced the acquisition of LumaBridge, a specialized U.S.-based clinical CRO with deep expertise in oncology trials.

• Health Equity Research Goes Global—Without Waiting For Perfect Data

  Value in Health Regional Issues published a special research collection showing meaningful progress in health equity across regions with varying data environments and policy needs.

• International Study Confirms Universal Digital Health Framework

  Value in Health published an international study showing the PICOTS‑ComTeC framework is an effective standard for defining patient-facing digital health interventions.

• ISPOR Announces New Executive Director

  ISPOR—The Professional Society for Health Economics and Outcomes Research has announced that Kelly Saldaña has been appointed as executive director for the ISPOR Institute for Healthcare Transformation.

• Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment

  Quotient Sciences, a leading integrated CRDMO, announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

• Sygnature Discovery Unveils Strategic Rebrand To Cement Status As A Global Drug Discovery Partner

  Sygnature Discovery, a leading drug discovery contract research organisation (CRO), has today announced a strategic brand relaunch, including a new website, cementing its position as a global drug discovery partner.